Multidrug-resistant tuberculosis around the world: what progress has been made?
Abstract
Multidrug-resistant tuberculosis (MDR-TB) (resistance to at
least isoniazid and rifampicin) will influence the future of
global TB control. 88% of estimated MDR-TB cases occur in
middle- or high-income countries, and 60% occur in Brazil,
China, India, the Russian Federation and South Africa.
The
World Health Organization collects country data annually to
monitor the response to MDR-TB. Notification, treatment
enrolment and outcome data were summarised for 30 countries,
accounting for >90% of the estimated MDR-TB cases among
notified TB cases worldwide.
In 2012, a median of 14%
(interquartile range 6–50%) of estimated MDR-TB cases were
notified in the 30 countries studied. In 15 of the 30 countries,
the number of patients treated for MDR-TB in 2012 (71 681) was
>50% higher than in 2011. Median treatment success was 53%
(interquartile range 40–70%) in the 25 countries reporting
data for 30 021 MDR-TB cases who started treatment in 2010.
Although
progress has been noted in the expansion of MDR-TB care, urgent
efforts are required in order to provide wider access to
diagnosis and treatment in most countries with the highest
burden of MDR-TB.
Download the full article from here.
Source:
European Respiratory Journal
